Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
We have previously described an High prevalence of heparin induced thrombocytopenia with thrombosis (HITT) among patients with essential thrombocythemia carrying V 617 F mutation . The JAK2 V617F mutation has been demonstrated to be the main molecular marker of Philadelphia-negative chronic myeloproliferative neoplasms, occurring in > 90% of patients with polycythemia Vera and in about half of all of the patients with ET [2, 3, 4, 5].
We studied 108 ET patients on heparin for treatment of previous thrombotic events or in thromboprophilaxis. The study was conducted according to good clinical and laboratory practice rules and the principles of the Declaration of Helsinki, and the Ospedale Sacco and IRCCS Policlinico of Milan Ethics Review Committee approved the protocol. Fifty-eight of them carried JAK 2 V617F mutation while 50 patients were wild type for the mutation. Ten patients, among those with JAK 2 V617F mutation after a median of 10 days from heparin treatment...
- 1.Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L (2018) High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. J Thromb Thrombolysis 45(1):106–113. https://doi.org/10.1007/s11239-017-1566-1 CrossRefGoogle Scholar